CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will receive only $55.00 in cash for each share of Sierra that they own.
If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email (dk@kclasslaw.com), or visit https://kclasslaw.com/cases/ma/nasdaqgm-srra/ to learn more.
Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.
